Page last updated: 2024-11-02

pamidronate and Jaw Diseases

pamidronate has been researched along with Jaw Diseases in 70 studies

Jaw Diseases: Diseases involving the JAW.

Research Excerpts

ExcerptRelevanceReference
" Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years."9.14Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010)
"The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model."7.76Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010)
"A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone."7.76An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010)
" The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency."7.74A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007)
"Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration."7.74Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008)
" Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years."5.14Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. ( Abildgaard, N; Ahlberg, L; Andersen, NF; Carlson, K; Dahl, IM; Fayers, P; Gimsing, P; Gluud, C; Gregersen, H; Hjorth, M; Hjorth-Hansen, H; Juliusson, G; Knudsen, LM; Linder, O; Mylin, A; Nesthus, I; Nielsen, JL; Turesson, I; Vangsted, A; Waage, A; Westin, J; Wisløff, F, 2010)
"Of 73 patients, 68 (93%) were treated with pamidronate or zoledronate; 69 (94%) patients suffered from malignant diseases, 3 (5%) had osteoporosis, and 1 (1%) had Paget's disease."4.83[Bisphosphonate-associated osteonecrosis of the jaw]. ( Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T, 2006)
"The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model."3.76Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010)
"A total of 18 cases of osteonecrosis were recorded in the group administered pamidronate and dexamethasone."3.76An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. ( Camacho-Alonso, F; Gómez-García, F; López-Jornet, P; Molina-Miñano, F; Vicente-Ortega, V, 2010)
" The purpose of this study was to determine the incidence of jaw necrosis among a homogeneous population of multiple myeloma patients receiving the bisphosphonate pamidronate, to investigate risk factors and comorbidities that increase the risk and to characterize the radiographic changes on conventional dental radiographs in terms of type and frequency."3.74A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. ( Jadu, F; Lee, L; Pharoah, M; Reece, D; Wang, L, 2007)
"Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisphosphonates administration."3.74Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. ( Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A, 2008)
"Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid."3.73Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005)
" We present two patients with multiple myeloma who developed osteonecrosis of the jaws on intravenous treatment with zolendronic acid and pamidronate, respectively."3.73[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis]. ( Gregersen, H; Neumann, B, 2006)
" Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures."3.73[Osteonecrosis associated with the use of biphosphonates: Case report]. ( Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I, 2006)
" The preliminary results seem to suggest that biphosphonate-associated osteonecrosis can be well controlled by a nonsurgical protocol consisting in long-term administration of antibiotics."2.73Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. ( Felicetti, L; Gissi, DB; Marchetti, C; Montebugnoli, L; Pelliccioni, GA; Pizzigallo, A, 2007)
"Pamidronate appears to be an effective and well-tolerated therapeutic option for patients with fibrous dysplasia."2.71Treatment of monostotic fibrous dysplasia with pamidronate. ( Godzinski, J; Klempous, J; Kos, M; Luczak, K, 2004)
"Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)."1.42Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015)
"Using the Pmetrics package and published data, we designed a population pharmacokinetic model of pamidronate concentration in plasma and bone and derived a toxic bone BP threshold of 0."1.39Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. ( Jelliffe, RW; Jones, AC; Kiss, A; LaVallee, C; Le, AD; Lee, P; Neely, M; Sedghizadeh, PP, 2013)
"In this cohort study, patients with multiple myeloma (MM) on intravenous BP therapy were enrolled over 1 year."1.37Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. ( Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D, 2011)
"Patients with breast cancer demonstrated a reduced risk for ONJ development, which turned out to be nonsignificant after adjustment for other variables."1.35Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. ( Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K, 2009)
"In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ."1.35Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. ( Dodson, TB; Wessel, JH; Zavras, AI, 2008)
" Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure."1.34Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007)
"Multiple myeloma was the most common comorbidity."1.34Bisphosphonates and jaw osteonecrosis: the UAMS experience. ( Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E, 2007)
"Sixty-two (52."1.33Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005)
"The reasons for bisphosphonate treatment were multiple myeloma in 12 patients, breast cancer with bone metastasis in four patients and histiocytosis X in one patient."1.33Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. ( Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A, 2006)
"Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously."1.33Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006)

Research

Studies (70)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's52 (74.29)29.6817
2010's18 (25.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Souza Tolentino, E1
de Castro, TF1
Michellon, FC1
Passoni, ACC1
Ortega, LJA1
Iwaki, LCV1
da Silva, MC1
Owosho, AA1
Liang, STY1
Sax, AZ1
Wu, K1
Yom, SK1
Huryn, JM1
Estilo, CL1
Gabbert, TI1
Hoffmeister, B1
Felsenberg, D1
La Verde, N1
Bareggi, C1
Garassino, M1
Borgonovo, K1
Sburlati, P1
Pedretti, D1
Bianchi, C1
Perrone, S1
Mihali, D1
Cobelli, S1
Mantica, C1
Rizzo, A1
Farina, G1
Chahine, C1
Cheung, MS1
Head, TW1
Schwartz, S1
Glorieux, FH1
Rauch, F1
Alons, K1
Kuijpers, SC1
de Jong, E1
van Merkesteyn, JP1
Geusens, P1
Lazarovici, TS1
Yahalom, R1
Taicher, S1
Elad, S1
Hardan, I1
Yarom, N1
Stanton, DC1
Balasanian, E1
Stockmann, P2
Hinkmann, FM1
Lell, MM1
Fenner, M1
Vairaktaris, E1
Neukam, FW1
Nkenke, E2
O'Ryan, FS1
Khoury, S1
Liao, W1
Han, MM1
Hui, RL1
Baer, D1
Martin, D1
Liberty, D1
Lo, JC1
Hoefert, S1
Schmitz, I1
Tannapfel, A1
Eufinger, H1
Vahtsevanos, K2
Kyrgidis, A1
Verrou, E2
Katodritou, E1
Triaridis, S1
Andreadis, CG1
Boukovinas, I1
Koloutsos, GE1
Teleioudis, Z2
Kitikidou, K1
Paraskevopoulos, P1
Zervas, K2
Antoniades, K1
Crawford, BS1
McNulty, RM1
Kraut, EH1
Turowski, RC1
Scoletta, M1
Arduino, PG1
Dalmasso, P1
Broccoletti, R1
Mozzati, M1
Ficarra, G1
Beninati, F1
López-Jornet, P2
Camacho-Alonso, F2
Molina-Miñano, F2
Gómez-García, F2
Vicente-Ortega, V2
Gimsing, P1
Carlson, K1
Turesson, I1
Fayers, P1
Waage, A1
Vangsted, A1
Mylin, A1
Gluud, C1
Juliusson, G1
Gregersen, H2
Hjorth-Hansen, H1
Nesthus, I1
Dahl, IM1
Westin, J1
Nielsen, JL1
Knudsen, LM1
Ahlberg, L1
Hjorth, M1
Abildgaard, N1
Andersen, NF1
Linder, O1
Wisløff, F1
Wehrhan, F1
Hyckel, P1
Amann, K1
Ries, J1
Schlegel, K1
Neukam, F1
Katz, J1
Gong, Y1
Salmasinia, D1
Hou, W1
Burkley, B1
Ferreira, P1
Casanova, O1
Langaee, TY1
Moreb, JS1
Nicolatou-Galitis, O1
Papadopoulou, E1
Sarri, T1
Boziari, P1
Karayianni, A1
Kyrtsonis, MC1
Repousis, P1
Barbounis, V1
Migliorati, CA1
Ngamphaiboon, N1
Frustino, JL1
Kossoff, EB1
Sullivan, MA1
O'Connor, TL1
Martínez-Canovas, A1
Cella, L1
Oppici, A1
Arbasi, M1
Moretto, M1
Piepoli, M1
Vallisa, D1
Zangrandi, A1
Di Nunzio, C1
Cavanna, L1
Mawardi, H1
Giro, G1
Kajiya, M1
Ohta, K1
Almazrooa, S1
Alshwaimi, E1
Woo, SB2
Nishimura, I1
Kawai, T1
Bartl, R1
Thumbigere-Math, V1
Tu, L1
Huckabay, S1
Dudek, AZ1
Lunos, S1
Basi, DL1
Hughes, PJ1
Leach, JW1
Swenson, KK1
Gopalakrishnan, R1
Sedghizadeh, PP1
Jones, AC1
LaVallee, C1
Jelliffe, RW1
Le, AD1
Lee, P1
Kiss, A1
Neely, M1
Marx, RE2
Tarassoff, P1
Csermak, K1
Kos, M1
Luczak, K1
Godzinski, J1
Klempous, J1
Carter, GD1
Goss, AN1
Greenberg, MS1
Jimenez-Soriano, Y1
Bagan, JV1
Durie, BG1
Katz, M1
Crowley, J1
Hande, K1
Richardson, PG1
Sarathy, AP1
Bourgeois, SL1
Goodell, GG1
Sawatari, Y1
Fortin, M1
Broumand, V1
Bamias, A1
Kastritis, E1
Bamia, C1
Moulopoulos, LA1
Melakopoulos, I1
Bozas, G1
Koutsoukou, V1
Gika, D1
Anagnostopoulos, A1
Papadimitriou, C1
Terpos, E2
Dimopoulos, MA1
Abi Najm, S1
Lysitsa, S1
Carrel, JP1
Lesclous, P1
Lombardi, T1
Samson, J1
Pastor-Zuazaga, D1
Garatea-Crelgo, J1
Martino-Gorbea, R1
Etayo-Pérez, A1
Sebastián-López, C1
Abu-Id, MH2
Açil, Y2
Gottschalk, J2
Kreusch, T2
Alexander, RE1
Farrar, SK1
Thakkar, SG1
Isada, C1
Smith, J1
Karam, MA1
Reed, J1
Tomford, JW1
Englund, K1
Richmond, M1
Licata, A1
Hatch, C1
Hussein, MA1
Dimitrakopoulos, I1
Magopoulos, C1
Karakasis, D1
Neumann, B1
Banti, A1
Mihou, D1
Krikelis, D1
Weeda, LW1
Kademani, D1
Koka, S1
Lacy, MQ1
Rajkumar, SV1
Wutzl, A1
Eisenmenger, G1
Hoffmann, M1
Czerny, C1
Moser, D1
Pietschmann, P1
Ewers, R1
Baumann, A1
Nastro, E1
Musolino, C1
Allegra, A1
Oteri, G1
Cicciù, M1
Alonci, A1
Quartarone, E1
Alati, C1
De Ponte, FS1
Anguita C, T1
Agurto P, J1
Roa E, I1
Laissle C, G1
Merigo, E1
Manfredi, M1
Meleti, M1
Guidotti, R1
Ripasarti, A1
Zanzucchi, E1
D'Aleo, P1
Corradi, D1
Corcione, L1
Sesenna, E1
Ferrari, S1
Poli, T1
Bonaninil, M1
Vescovi, P1
Dannemann, C1
Grätz, KW1
Riener, MO1
Zwahlen, RA1
Clarke, BM1
Boyette, J1
Vural, E1
Suen, JY1
Anaissie, EJ1
Stack, BC1
Corso, A1
Varettoni, M1
Zappasodi, P1
Klersy, C1
Mangiacavalli, S1
Pica, G1
Lazzarino, M1
Montebugnoli, L1
Felicetti, L1
Gissi, DB1
Pizzigallo, A1
Pelliccioni, GA1
Marchetti, C1
Shenker, NG1
Jawad, AS1
Jadu, F1
Lee, L1
Pharoah, M1
Reece, D1
Wang, L1
Brown, JJ1
Ramalingam, L1
Zacharin, MR1
Warnke, PH1
Springer, I1
Wiltfang, J1
Russo, PA1
Bianchi, ML1
Limonta, C1
Frasunkiewicz, J1
Biggioggero, M1
Vai, S1
Bedogni, A1
Blandamura, S1
Lokmic, Z1
Palumbo, C1
Ragazzo, M1
Ferrari, F1
Tregnaghi, A1
Pietrogrande, F1
Procopio, O1
Saia, G1
Ferretti, M1
Bedogni, G1
Chiarini, L1
Ferronato, G1
Ninfo, V1
Lo Russo, L1
Lo Muzio, L1
Nocini, PF1
Kohno, N1
Wessel, JH1
Dodson, TB1
Zavras, AI1
Sari, E1
Bulut, N1
Altundag, K1
Landesberg, R1
Cozin, M1
Cremers, S1
Woo, V1
Kousteni, S1
Sinha, S1
Garrett-Sinha, L1
Raghavan, S1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.[NCT00376883]Phase 3500 participants Interventional2000-01-31Completed
Development Of A Predictive Score For Maxillary Osteochimionecrosis After Invasive Oral Surgery In Patients Treated Whith Biphosphonates Or Biotherapies: The PREV-ONM Study[NCT04257721]45 participants (Actual)Observational2019-10-10Terminated (stopped due to rate of inclusions too low)
Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws (MRONJ) Stages I and II, a Quasi-experimental Clinical Trial With Discovery of Salivary Biomarkers[NCT04584840]50 participants (Anticipated)Interventional2020-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for pamidronate and Jaw Diseases

ArticleYear
Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.
    Head & neck, 2019, Volume: 41, Issue:12

    Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservati

2019
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
    Current osteoporosis reports, 2009, Volume: 7, Issue:1

    Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac

2009
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
    Head and neck pathology, 2007, Volume: 1, Issue:2

    Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injectio

2007
[Bisphosphonate-associated osteonecrosis of the jaw].
    Mund-, Kiefer- und Gesichtschirurgie : MKG, 2006, Volume: 10, Issue:2

    Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Im

2006
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
    International journal of clinical oncology, 2008, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms;

2008

Trials

4 trials available for pamidronate and Jaw Diseases

ArticleYear
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.
    Clinical oral investigations, 2010, Volume: 14, Issue:3

    Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow-

2010
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation A

2010
Treatment of monostotic fibrous dysplasia with pamidronate.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2004, Volume: 32, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Diphosphonates; Facial Pain; Female; Fibr

2004
Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 104, Issue:4

    Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Bo

2007

Other Studies

61 other studies available for pamidronate and Jaw Diseases

ArticleYear
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2018, Volume: 125, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Ja

2018
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem

2015
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:11

    Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femal

2008
Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate.
    The Journal of pediatrics, 2008, Volume: 153, Issue:5

    Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Diphosphonates; Female; Follow

2008
Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2009, Volume: 107, Issue:2

    Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic

2009
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bac

2009
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Femal

2009
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:7

    Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis

2009
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
    Clinical oral investigations, 2010, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di

2010
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates;

2009
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Cancer investigation, 2009, Volume: 27, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms;

2009
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 110, Issue:1

    Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni

2010
An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2010, Volume: 39, Issue:9

    Topics: Animals; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Drug Combinations; Glucoco

2010
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
    Oral diseases, 2011, Volume: 17, Issue:4

    Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogen

2011
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
    International journal of oral and maxillofacial surgery, 2011, Volume: 40, Issue:6

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collag

2011
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2011, Volume: 112, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Co

2011
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Clinical breast cancer, 2011, Volume: 11, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anti

2011
Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2011, Volume: 69, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bone Density Conservation Agents; Dexamethas

2011
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw.
    Head & face medicine, 2011, Aug-17, Volume: 7

    Topics: Aged; Diphosphonates; Female; Humans; Injections, Intralesional; Jaw Diseases; Osteonecrosis; Osteop

2011
A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw.
    Journal of dental research, 2011, Volume: 90, Issue:11

    Topics: Animals; Anti-Bacterial Agents; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cell Sur

2011
[Inflammation of the jaws during treatment with bisphosphonates].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41

    Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas

2011
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
    American journal of clinical oncology, 2012, Volume: 35, Issue:4

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections,

2012
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2013, Volume: 115, Issue:2

    Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone De

2013
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:9

    Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat

2003
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:9

    Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat

2003
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:9

    Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat

2003
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:9

    Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronat

2003
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:10

    Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecros

2003
Bisphosphonates and avascular necrosis of the jaws.
    Australian dental journal, 2003, Volume: 48, Issue:4

    Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Tooth Extraction; Zole

2003
Intravenous bisphosphonates and osteonecrosis.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2004, Volume: 98, Issue:3

    Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Di

2004
[Rapid drug information].
    Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2005, Volume: 48, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info

2005
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
    Medicina oral, patologia oral y cirugia bucal, 2005, Jul-01, Volume: 10 Suppl 2

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Int

2005
Osteonecrosis of the jaw and bisphosphonates.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis;

2005
Osteonecrosis of the jaw and bisphosphonates.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis;

2005
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
    Journal of endodontics, 2005, Volume: 31, Issue:10

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease

2005
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11

    Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas

2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla

2005
[Bisphosphonates-related jaw osteonecrosis].
    Presse medicale (Paris, France : 1983), 2005, Sep-10, Volume: 34, Issue:15

    Topics: Adolescent; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Human

2005
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
    Medicina oral, patologia oral y cirugia bucal, 2006, Jan-01, Volume: 11, Issue:1

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalce

2006
Relationship between periodontal disease and systemic diseases.
    Texas dental journal, 2006, Volume: 123, Issue:2

    Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; D

2006
The buzz about bisphosphonates.
    LDA journal, 2005,Fall, Volume: 64, Issue:3

    Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid

2005
Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
    Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Midd

2006
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
    International journal of oral and maxillofacial surgery, 2006, Volume: 35, Issue:7

    Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles;

2006
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
    Ugeskrift for laeger, 2006, May-22, Volume: 168, Issue:21

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mult

2006
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
    British journal of haematology, 2006, Volume: 134, Issue:6

    Topics: Aged; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Jaw Diseases; Male; M

2006
Drug induced osteonecrosis of the jaws.
    The Journal of the Tennessee Dental Association, 2006,Spring, Volume: 86, Issue:2

    Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density; Bone Densit

2006
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
    Mayo Clinic proceedings, 2006, Volume: 81, Issue:8

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazole

2006
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wiener klinische Wochenschrift, 2006, Volume: 118, Issue:15-16

    Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fol

2006
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
    Acta haematologica, 2007, Volume: 117, Issue:3

    Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem

2007
[Osteonecrosis associated with the use of biphosphonates: Case report].
    Revista medica de Chile, 2006, Volume: 134, Issue:9

    Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease

2006
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
    Acta bio-medica : Atenei Parmensis, 2006, Volume: 77, Issue:2

    Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv

2006
I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about?
    DukeMedicine healthnews, 2006, Volume: 12, Issue:11

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonec

2006
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
    Bone, 2007, Volume: 40, Issue:4

    Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Disea

2007
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 136, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental

2007
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
    Leukemia, 2007, Volume: 21, Issue:7

    Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Inc

2007
Bisphosphonates and osteonecrosis of the jaw.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:7

    Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteopo

2007
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:12

    Topics: Diphosphonates; Humans; Incidence; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Radio

2007
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Clinical endocrinology, 2008, Volume: 68, Issue:6

    Topics: Adolescent; Bone Density Conservation Agents; Child; Cohort Studies; Diphosphonates; Humans; Imidazo

2008
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2008, Volume: 36, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphona

2008
Comment on: Bisphosphonates and osteonecrosis of the jaw.
    Rheumatology (Oxford, England), 2008, Volume: 47, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Alendronate; Child; Child, Preschool; Diphosphonates; Dose-

2008
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 105, Issue:3

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphospho

2008
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:4

    Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Co

2008
Osteonecrosis of the jaw.
    Journal of the American Dental Association (1939), 2008, Volume: 139, Issue:4

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Dis

2008
Inhibition of oral mucosal cell wound healing by bisphosphonates.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:5

    Topics: Animals; Apoptosis; Bone Density Conservation Agents; Caspase 3; Cell Proliferation; Cells, Cultured

2008